Illumina, Inc. $ILMN Shares Sold by Eagle Health Investments LP

Posted by Brian Himes on Jul 28th, 2026

Eagle Health Investments LP lowered its holdings in shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) by 18.9% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 187,413 shares of the life sciences company’s stock after selling 43,748 shares during the period. Illumina accounts for approximately 4.0% of Eagle Health Investments LP’s holdings, making the stock its 8th largest position. Eagle Health Investments LP’s holdings in Illumina were worth $23,101,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Elyxium Wealth LLC acquired a new stake in shares of Illumina in the fourth quarter valued at approximately $25,000. Creative Capital Management Investments LLC boosted its stake in shares of Illumina by 160.0% during the 4th quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock worth $26,000 after acquiring an additional 120 shares during the period. TD Waterhouse Canada Inc. acquired a new position in shares of Illumina during the 4th quarter worth approximately $26,000. Laurel Wealth Advisors LLC acquired a new position in shares of Illumina during the 4th quarter worth approximately $26,000. Finally, Activest Wealth Management raised its stake in Illumina by 671.9% in the 4th quarter. Activest Wealth Management now owns 247 shares of the life sciences company’s stock valued at $32,000 after acquiring an additional 215 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on ILMN. Citigroup raised their price target on Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a report on Monday, May 4th. Leerink Partners upped their price objective on shares of Illumina from $175.00 to $210.00 and gave the company an “outperform” rating in a report on Friday, July 17th. Piper Sandler increased their price objective on shares of Illumina from $170.00 to $200.00 and gave the company an “overweight” rating in a research report on Wednesday, July 1st. Daiwa Securities Group upgraded shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 target price for the company in a research note on Thursday, May 14th. Finally, Weiss Ratings upgraded shares of Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, June 3rd. Nine analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $156.88.

Read Our Latest Stock Report on Illumina

Insider Buying and Selling

In other news, SVP Patricia Leckman sold 783 shares of the company’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $162.59, for a total transaction of $127,307.97. Following the completion of the sale, the senior vice president directly owned 21,259 shares in the company, valued at approximately $3,456,500.81. This represents a 3.55% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Scott M. Davies sold 615 shares of the stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $180.00, for a total value of $110,700.00. Following the sale, the insider directly owned 20,953 shares in the company, valued at approximately $3,771,540. This trade represents a 2.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 1,003,769 shares of company stock worth $155,710,908. 2.90% of the stock is owned by corporate insiders.

Illumina Stock Performance

NASDAQ ILMN opened at $189.47 on Tuesday. The firm has a 50-day moving average price of $172.20 and a two-hundred day moving average price of $145.73. Illumina, Inc. has a 12-month low of $88.00 and a 12-month high of $199.14. The company has a market capitalization of $28.67 billion, a P/E ratio of 34.45, a P/E/G ratio of 2.87 and a beta of 1.47. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56.

Illumina (NASDAQ:ILMN – Get Free Report) last announced its earnings results on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, topping the consensus estimate of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The company had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same period last year, the firm earned $0.97 earnings per share. The business’s revenue for the quarter was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Analysts anticipate that Illumina, Inc. will post 5.22 earnings per share for the current year.

About Illumina

(Free Report)

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.